Marvell’s Trillion-Dollar Target

Jon Quast introduced Marvell’s proposed acquisition of Lumentum, valued at $115 billion—far above Microsoft’s $69 billion Activision deal and Broadcom’s $61 billion VMware deal. Matt Frankel explained that Lumentum makes lasers and optical components that convert electrical signals into light, allowing data-center connections to operate faster, with greater capacity and efficiency than copper wiring. Lumentum’s revenue rose 137% year over year in its latest quarter, it expects 27% sequential growth in the next quarter, and its capacity is effectively sold out through early 2029.

Rachel Warren described Marvell as a designer and manufacturer of semiconductors and data-infrastructure products, including custom ASICs, XPU processors, networking chips, and digital signal processors that clean up electrical signals before they reach a laser. Lumentum operates specialized fabs that grow indium phosphide, a rare material used in high-speed AI lasers, and assembles optical transceivers for AI server racks. Rachel said Marvell wants this capability to offer hyperscalers such as Alphabet and AWS an alternative to Broadcom’s ecosystem.

Matt said controlling more of the AI-infrastructure supply chain matters because lasers are scarce and Lumentum’s production is already committed for years. Broadcom is currently the only rival able to design chips, lasers, and modules together; completing the acquisition would give Marvell comparable capabilities. Rachel added that AI expansion is constrained by physical manufacturing capacity as much as by chip design, so bringing Lumentum’s fabs into Marvell could shorten delivery timelines for hyperscalers and strengthen Marvell’s position through 2030 and beyond.

Marvell plans to issue 4.5 Marvell shares for every Lumentum share, making the transaction an all-stock deal rather than paying cash or taking on major new debt. The announced $115 billion value and implied $1,132 per Lumentum share assume Marvell trades at $252, its pre-rumor price. After Marvell fell about 25%, those 4.5 shares were worth roughly $857, illustrating that Lumentum holders do not receive a fixed $1,132. Rachel noted that new shares would give Lumentum investors 33% of the combined company.

The deal is not expected to close until the first half of 2028, and both speakers expect a complex regulatory review and lengthy integration. Rachel said Marvell stock could act like “dead money” or trade sideways near term, especially because the company is blending a capital-intensive manufacturing business into a lighter-overhead chip-design operation. Matt’s bull case is that investors can eventually own two strong AI-infrastructure beneficiaries at roughly a 25% discount, but he warned that AI spending could weaken during the 18-month-plus wait and stopped short of calling Marvell a buy.

Rachel recalled panicking, checking her phone constantly, and watching paper losses during her first major crash after the COVID-era bubble burst. In hindsight, she had confused an inflated market with good investing and bought some overvalued businesses. Her key test now is whether the company still grows revenue, expands profitability, carries limited debt, and retains the original growth thesis. If the business remains sound and only the shares face industry or market pressure, she generally prefers holding. She also now balances growth stocks with value-oriented healthcare and dividend holdings.

Matt said the S&P 500 fell 57% from its October 2007 peak to its March 2009 bottom; his AIG shares lost about 95%, and although he did not sell, he stayed on the sidelines. He emphasized that recovering from a 50% loss requires a 100% gain, making downturns opportunities when the business remains intact. An index eventually recovered, but individual companies such as some financial firms did not. For 20-year-old Ben, the speakers recommended continuing to invest new money regularly, since decades of contributions and compounding matter more than today’s drawdown.